A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study To Assess The Safety, Tolerability, And Pharmacokinetics Of PF-06678552 After Fed And Fasted Administration Of Single Escalating Oral Doses In Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 02 May 2014
At a glance
- Drugs PF 6678552 (Primary)
- Indications Hypercholesterolaemia
- Focus Adverse reactions
- Sponsors Pfizer
- 02 May 2014 According to ClinicalTrials.gov record, status changed from recruiting to completed.
- 13 Jan 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
- 04 Dec 2013 New trial record